{"id":46922,"date":"2022-08-04T12:02:00","date_gmt":"2022-08-04T10:02:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/north-america-idiopathic-pulmonary-fibrosis-market-report-2022-growth-of-5-6-expected-annually-driven-by-key-players-gni-group-astrazeneca-others-shionogi-co-researchandmarkets-com\/"},"modified":"2022-08-04T12:02:00","modified_gmt":"2022-08-04T10:02:00","slug":"north-america-idiopathic-pulmonary-fibrosis-market-report-2022-growth-of-5-6-expected-annually-driven-by-key-players-gni-group-astrazeneca-others-shionogi-co-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/north-america-idiopathic-pulmonary-fibrosis-market-report-2022-growth-of-5-6-expected-annually-driven-by-key-players-gni-group-astrazeneca-others-shionogi-co-researchandmarkets-com\/","title":{"rendered":"North America Idiopathic Pulmonary Fibrosis Market Report 2022: Growth of 5.6% Expected Annually, Driven by Key Players GNI Group, AstraZeneca & Others Shionogi & Co, – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “North America Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe North America Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of 5.6% CAGR during the forecast period.\n<\/p>\n

\nWhile it’s difficult to define who develops IPF, some studies showcase that more males are diagnosed with the disease than females. Age is also a determining factor in IPF. In a vast number of researches, older age has been identified as a prevalent diagnostic factor for IPF.\n<\/p>\n

\nAccording to the Centers for Disease Control and Prevention, more than 14% (34.1 million) of adults in the United States smoked tobacco in 2019. As per the American IPF Foundation, the incidence of idiopathic pulmonary fibrosis (IPF) has doubled in the last ten years. In the United States, an estimated 50,000 people die from IPF each year, which is higher than breast cancer.\n<\/p>\n

\nMoreover, the Centers for Disease Control and Prevention recently discovered a statistically significant cluster of IPF patients diagnosed at a Virginia medical centre. Because of the increased frequency of the condition, as well as the rising geriatric population and smoking habits, the United States is a prominent country of the regional market. In the United States, idiopathic pulmonary fibrosis treatment costs $100,000 per year, according to data published in the American Journal of Managed Care (AJMC) in 2014.\n<\/p>\n

\nThe US market dominated the North America Idiopathic Pulmonary Fibrosis Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $1,269.5 million by 2027. The Canada market is poised to grow at a CAGR of 8% during (2021 – 2027). Additionally, The Mexico market is expected to display a CAGR of 7% during (2021 – 2027).\n<\/p>\n

\nScope of the Study<\/strong>\n<\/p>\n

\nMarket Segments Covered in the Report:<\/strong>\n<\/p>\n

\nBy Drug Type<\/strong>\n<\/p>\n